Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Heart failure linked to heavy energy drink consumption
Fri April 16th - Drinking excessive energy drinks could be linked to a young man’s heart failure, according to doctors who treated a 21-year-old who consumed four cans a day for two years. More
Shift workers' heart health linked to body clock
Fri April 16th - The risk of heart disease becomes greater the more an individual works outside of their natural body clock, new research suggests. More
Infection much greater risk than vaccines for thrombotic events
Fri April 16th - Cerebral venous thrombosis has been a significant complication of COVID-19 at a rate far higher than seen after vaccination, British researchers have reported. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

Therapy might block multiple sclerosis autoimmune process

Wednesday February 17th 2021

A new study has shown how harmful immune cells travel to the brain in people with multiple sclerosis and lead to disease progression.

The discovery has opened up the possibility of using treatments to block the autoimmune processes associated with the disease.

The disease-causing population of immune cells has been studied by Dr Hayley Evans of the University of Oxford, UK, and colleagues at the University of Hamburg, Germany.

They examined samples from deceased late stage patients and identified individual immune cells that travel to the brain using a cutting-edge technology called spatial transcriptomics.

The gene signatures of these cells were located on a detailed physical map, showing that they were localised in areas of brain damage. The action of these cells is reported in yesterday's (16 February) issue of Med a journal by Cell Press.

Dr Hayley Evans explains: "We were able to generate high quality data, maximising the use of precious patient samples. This allowed us to reveal novel characteristics of this population, which could be used to develop new treatments that eliminate them before they enter the brain and drive disease."

The team tested a treatment called natalizumab which is known to block cell movement through the blood brain barrier. This was capable of retaining these cells in the blood, suggesting that it could become part of a new treatment for patients.

Co-author Professor Lars Fugger says: "Our results suggest that the colonisation of the brain by immune cells could be an important factor in the therapeutic resistance of late-stage multiple sclerosis.

"At the same time, we demonstrate that these cells can be mobilised to the blood at an early disease stage, raising the possibility that they could be reached by novel therapeutics."

Evans, H. et al. Identifying CNS-colonizing T cells as potential therapeutic targets for progressive multiple sclerosis. Med 16 February 2021; doi: 10.1016/j.medj.2021.01.006


Tags: Brain & Neurology | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)